Comparative Pharmacology
Head-to-head clinical analysis: FALMINA versus HAILEY FE 1 5 30.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FALMINA versus HAILEY FE 1 5 30.
FALMINA vs HAILEY FE 1.5/30
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the CNS by inhibiting the reuptake of serotonin at the synaptic cleft, leading to increased serotonin levels.
Combination estrogen-progestin contraceptive that suppresses gonadotropin release (FSH and LH) from the pituitary, inhibiting ovulation. Additionally, increases viscosity of cervical mucus and alters endometrial receptivity.
FALMINA (fictitious drug): 500 mg orally every 12 hours.
One tablet orally once daily for 21 consecutive days, followed by 7 days of placebo tablets.
None Documented
None Documented
Terminal elimination half-life 12-15 hours; in severe renal impairment (CrCl <30 mL/min) extends to 30-40 hours, requiring dose adjustment.
Ethinyl estradiol: terminal half-life ~17-24 hours; norethindrone: terminal half-life ~5-14 hours (mean 11 hours). The clinical significance is that steady-state is reached within 5-7 days.
Primarily renal (85% unchanged drug, 10% as glucuronide conjugate); biliary/fecal 5%.
Ethinyl estradiol is primarily excreted renally (40-45%) and via bile/feces (45-55%). Norethindrone is excreted 50-60% renally and 30-40% fecally.
Category C
Category C
Oral Contraceptive
Oral Contraceptive